Compare GSBC & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSBC | ANNX |
|---|---|---|
| Founded | 1923 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.6M | 873.3M |
| IPO Year | 1996 | 2020 |
| Metric | GSBC | ANNX |
|---|---|---|
| Price | $79.49 | $4.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $65.00 | $16.50 |
| AVG Volume (30 Days) | 76.1K | ★ 2.3M |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 17.68 | N/A |
| EPS | ★ 2.99 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.56 | $16,320.74 |
| P/E Ratio | $26.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $53.76 | $2.32 |
| 52 Week High | $82.91 | $7.18 |
| Indicator | GSBC | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 37.57 |
| Support Level | $76.29 | $4.01 |
| Resistance Level | $82.19 | $5.63 |
| Average True Range (ATR) | 1.49 | 0.24 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 73.46 | 3.76 |
Great Southern Bancorp Inc is a bank holding company. Through its subsidiaries, the company mainly offers a variety of banking and banking-related services, such as accepting deposits, granting loans and advances, offering mobile banking services, issuing debit and credit cards, safe deposit boxes, ATM facilities, and other related products and services. These services are offered through full-service retail banking offices and loan production offices located across different states in the U.S., including Missouri, Iowa, Kansas, Minnesota, Nebraska, Arkansas, and others.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.